Axicabtagene Ciloleucel: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted axicabtagene ciloleucel, while CIPM (Spain) did not recommend it.
Assessment has run over 7.8 years, from 8 Aug 2018 at AWMSG (Wales) to 6 May 2026 at HAS (France).
AOTMIT (Poland) changed its position: not recommended on 12 Mar 2021, restricted by 7 Jun 2024, after a resubmission.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for axicabtagene ciloleucel, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 20 of 34 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for axicabtagene ciloleucel by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess axicabtagene ciloleucel, on 8 Aug 2018; DMC (Denmark) did not open a file until 27 Nov 2024 — a wide spread of 6.2 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 8 years in total.
10 of the 12 agencies here assessed axicabtagene ciloleucel more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
axicabtagene ciloleucel has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for axicabtagene ciloleucel reads 15 recommended, 5 not recommended, 4 restricted and 3 deferred to NICE, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 19 Dec 2024 | Yescarta — benefit assessment §35a | added benefit: minor (hint) | source |
| DMC (Denmark) | 27 Nov 2024 | Diffust storcellet B-celle lymfom, 2. linje | Anbefalet | source |
| ZIN (Netherlands) | 26 Jun 2024 | Advies - uitbreiding vergoeding axicabtagene ciloleucel (Yescarta®) voor de behandeling van lymfeklierkanker | advice published | source |
| AOTMIT (Poland) | 7 Jun 2024 | Yescarta reimbursement recommendation | recommended conditionally | source |
| SMC (Scotland) | 15 Jan 2024 | Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. | not recommended | source |
29 further decisions for axicabtagene ciloleucel, across 12 agencies, are not shown here. They include the most recent record on file, 6 May 2026 from HAS (France); its outcome is in the subscriber dataset. They link to 24 further source documents.
Related molecules
- loncastuximab tesirine — divergent outcome (recommended vs not recommended) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
Coverage: 34 decisions for axicabtagene ciloleucel from 12 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.